Last updated: May 24, 2026
Mitoxantrone hydrochloride supply is concentrated among a small set of established generic and API manufacturers that produce mitoxantrone as the active pharmaceutical ingredient (API) and/or finished lyophilized or solution dosage forms. For purchasing, procurement, and distribution planning, the actionable focus is on (1) verified API sourcing and DMF-supported supply chains, (2) finished-dose equivalents listed under the relevant FDA/NDC markets, and (3) downstream manufacturing capacity for sterile oncology injectables.
Who supplies mitoxantrone hydrochloride API and finished dosage forms?
Mitoxantrone hydrochloride is an oncology small-molecule and is typically supplied via two channels:
- API suppliers that file with FDA under Drug Master Files (DMFs) or supply to finished-dose manufacturers.
- Finished-dose manufacturers that hold the approved NDA/ANDA for mitoxantrone hydrochloride injection products marketed in the US (and equivalent dossiers in other jurisdictions).
What to target when evaluating API suppliers for mitoxantrone hydrochloride
For reliable sourcing, buyer due diligence normally targets:
- DMF coverage for mitoxantrone hydrochloride (API identity, assay, impurities, polymorph/solid form where applicable).
- Sterile manufacturing and aseptic fill-finish capabilities for the finished product (if sourcing finished dosage forms).
- Batch documentation package scope (CoA, endotoxin limits, sterility assurance, stability protocol).
- Regulatory history and inspection outcomes for manufacturing sites.
What finished-dose suppliers exist in the market
Mitoxantrone hydrochloride is widely marketed as an injectable oncology product. In most developed markets, procurement is executed through:
- US generic injectables distributors selling FDA-approved ANDA products
- Hospital purchasing via wholesalers using NDC-linked product catalog SKUs
- Parallel import or in-country manufacture in EU/UK and other jurisdictions
Which companies manufacture mitoxantrone hydrochloride for generic injection products?
The mitoxantrone hydrochloride injectable market is supplied mainly by generic injectables companies and their contracted sterile manufacturing partners. For procurement and licensing decisions, the practical supplier map is:
- ANDA/market authorization holders (finished dosage forms)
- Contract sterile manufacturers producing multiple oncology injectables under supply agreements
- API producers feeding finished-dose manufacturing via DMF or quality agreements
Common procurement reality for mitoxantrone
Even when a finished-dose brand or generic label appears to be from one company, the manufacturing network often includes:
- internal or contracted API production
- outsourced aseptic filling and packaging for sterile injection presentations
- secondary distribution through national wholesalers
What patents and exclusivity affect mitoxantrone hydrochloride supply?
Mitoxantrone hydrochloride is a legacy oncology drug. Patents and exclusivity are typically not the binding constraint for day-to-day supply in most markets; instead, supply is constrained by:
- aseptic fill-finish capacity for sterile injectables
- regulatory compliance history
- raw material availability and impurity profile controls at the API level
This environment usually supports multiple generic options, subject to localized shortages or manufacturing disruptions.
How many suppliers can source mitoxantrone hydrochloride injection in the US?
The correct method to size the supplier universe is to enumerate mitoxantrone hydrochloride injection products on the FDA market using:
- active NDC labels for mitoxantrone hydrochloride injection
- ANDA holders associated with those NDCs
- the corresponding API DMF links where available
Without enumerating current NDCs and ANDA holders from authoritative databases, any numeric “count” would be incomplete for procurement decisions.
What are the key regulatory filing structures for mitoxantrone hydrochloride supply?
Mitoxantrone supply chains typically involve multiple regulatory instruments:
- FDA DMFs for API (where the finished-dose applicant references an API manufacturer)
- ANDAs for generic finished products including chemistry, manufacturing, and controls (CMC)
- Quality agreements covering impurity specifications and change control notifications
In EU and other regulated markets, dossiers mirror these controls under EMA national procedures and local marketing authorization systems.
When do mitoxantrone hydrochloride shortages occur and what drives them?
Shortages for sterile oncology injectables typically stem from:
- sterile facility capacity limits or inspection-driven pauses
- API supply interruptions tied to impurity control excursions
- packaging line constraints (vial types, stoppers, carton/label formats)
- raw material lead-time and batch release delays
These drivers are more operational than patent-driven.
How does mitoxantrone hydrochloride compare with other anthracenedione oncology injectables for supplier risk?
Compared with newer oncology injectables, mitoxantrone generally has:
- more mature generic penetration
- a supplier set that is smaller than newer agents but often more substitutable
- risk concentrated in sterile fill-finish and API impurity management
What formulations and presentations are most commonly sourced?
Procurement for mitoxantrone hydrochloride usually targets sterile injectable presentations that align with:
- hospital IV oncology workflows
- vial sizes used in standard dosing regimens
- stability and handling constraints relevant to dilution and administration
Suppliers vary by presentation and vial configuration rather than by active ingredient alone.
What commercial and contracting considerations matter for mitoxantrone hydrochloride supply?
For contracting, buyers focus on:
- supply continuity and backup manufacturing sites
- change control terms and notice periods for API/sterile process changes
- temperature excursion handling and shipping lane qualification
- batch testing timelines and release lead-time SLAs
Key Takeaways
- Mitoxantrone hydrochloride supply is dominated by a limited ecosystem of API manufacturers and sterile injectable finished-dose makers.
- Procurement risk is usually driven by sterile capacity, regulatory compliance, and API impurity/batch release controls, not by active patent exclusivity.
- The most actionable supplier mapping for execution is NDC/ANDA enumeration (finished doses) combined with DMF-backed API sourcing (where available).
FAQs
-
How do I identify the correct mitoxantrone hydrochloride injection NDCs for supplier sourcing?
Use FDA label/NDC directories to match strength and package configuration to the market product list.
-
Do mitoxantrone hydrochloride suppliers differ by API vs finished sterile product manufacturing?
Yes. Many market labels rely on external API DMF references and contracted aseptic fill-finish sites.
-
What supplier qualification documents are typically required for mitoxantrone hydrochloride injectable?
CoA, impurity profiles, sterility assurance/bioburden documentation, endotoxin testing, and change control history tied to the manufacturing site.
-
What typically causes mitoxantrone hydrochloride shortage events?
Aseptic fill-finish capacity constraints, inspection or compliance actions, and API batch release delays due to impurity or process deviations.
-
Are there biosimilar-like substitutes for mitoxantrone hydrochloride?
No. Mitoxantrone hydrochloride is a small molecule; replacement options are generics or therapeutically similar anthracenedione oncology agents.
References
- FDA. Drug Master Files (DMF) and regulatory information. U.S. Food and Drug Administration.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. NDC directory and labeling information. U.S. Food and Drug Administration.
